VTE: What is the optimal duration of antithrombotic treatment?

Prof. Dimitrios A. Tsakiris, MD was born in Thessaloniki, Greece and obtained his Diploma of Medicine (1982) at the Medical School, Aristotle University of Thessaloniki, Greece. He started his training in Clinical Haematology at the AHEPA University Hospital in Thessaloniki and completed it at the University Hospital Basel in Basel, Switzerland, where he has been working since 1987. He holds a license for Clinical Haematology and Laboratory Haematology. He spent one year (1996) as a Research Associate in Platelet Research at the Mount Sinai School of Medicine, New York, NY, USA. He has held a professorship in Haematology at the Faculty of Medicine, University of Basel, Switzerland since 2004 and serves also as a visiting Professor of Hematology at the Medical School of the Aristotle University of Thessaloniki. He has served as Head of Haemostasis since 2009 and Head of Diagnostic Haematology and Haemostasis (2014-2021), as well as member of the Stem Cell Transplant and Cell-Therapy Center Basel at the University Hospital Basel, Switzerland. Since 2021 he has been Director of Thrombosis and Haemostasis and Co-Head Hematology at SYNLAB Suisse SA, Switzerland. His main fields of scientific interests are platelet activation, platelet disorders, diagnosis and treatment of bleeding disorders and thrombophilia, disorders of haemostasis and endothelial cells after stem cell transplants. He has presented over 140 peer-reviewed original articles and reviews.

Jerzy Windyga is the Head of the Department of Disorders of Haemostasis and Internal Medicine in the Institute of Haematology and Transfusion Medicine, Warsaw, Poland. Prof. Windyga obtained his medical degree from Warsaw Medical University. He later received his doctoral degree at the Institute of Haematology and Blood Transfusion in Warsaw, where he also completed his medical specialisations in internal medicine, haematology, and laboratory haematology. He has been a member of the Board of Directors of the WFH (2014-2018) and the Executive Board of the Polish Society of Haematology and Transfusion Medicine (2011-2019). He was the 2012–2016 chair of the Haemophilia Twinning Committee of the WFH. Dr Windyga has also been a member of the EUHANET Steering Committee. In 2013 Dr Windyga was the president of the 6th Congress of the European Association for Haemophilia and Allied Disorders (EAHAD). Since 2003, Professor Windyga has been a member of the Medical Board of the Polish Haemophilia Society, where he advises on recommendations for haemophilia management. In 2019 he has been appointed the Chair of the Advisory Board of the National Program of Haemophilia and Allied Disorders in Poland 2019-2023. He has authored and co-authored over 400 papers published both in Polish and international medical journals. His current research is focused on management of haemophilia and other inherited bleeding disorders, immune thrombocytopenia, thrombotic microangiopathies, porphyria as well as management of venous thromboembolism with a focus on thrombophilia and rare venous thromboses.